Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)

Organon

Status and phase: Completed; Phase 4

Conditions: Rhinitis Allergic; Asthma

Treatments: Drug: MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00380705

2006_033

0476-365

Details and patient eligibility

About

Allow physicians not familiar with anti-leukotriene based therapy to test it

Enrollment: 91 estimated patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Establish diagnosis of mild to moderate chronic asthma and/or allergic rhinitis currently on treatment
• Voluntary acceptance to participate in the study

Exclusion criteria

• Patients with cystic fibrosis
• Patients with known hypersensitivity to singulair or any of its components
• Patients with severe chronic asthma

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)